You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

CLINICAL TRIALS PROFILE FOR GALLIUM DOTATATE GA-68


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for GALLIUM DOTATATE GA-68

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01873248 ↗ Investigation of 68Ga-DOTATATE, as a PET Imaging Agent in Neuroendocrine Tumor Patients Completed Jonsson Comprehensive Cancer Center Phase 1/Phase 2 2013-08-26 This is a prospective, Phase 1-2, single center study in a total of 100 subjects with Neuroendocrine Tumors (NETs). Study participants will receive a one-time administration of 68Ga-DOTATATE and undergo a PET/CT imaging study, to investigate its suitability as a PET imaging agent for NETs.
NCT01967537 ↗ Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors Completed National Cancer Institute (NCI) Phase 2 2013-10-18 Background: - Neuroendocrine tumors (NETs) are rare but have been more common over the past decade. The only treatment for NETs is surgery, but most are found when they are too advanced for surgery. Researchers are looking for the best way to find NETs earlier, so that surgery can be successful. They want to test if the study drug can be used along with imaging devices to detect NETs. Objectives: - To see how well a new experimental imaging agent, 68Gallium-DOTATATE, detects unknown primary and metastatic NETs in the gastrointestinal system and pancreas. Eligibility: - Adults over 10 years old with a suspected NET or family history of NET. Design: - Participants will be screened with a medical history and physical exam, and have a blood test. - Participants will undergo three scans. For all of these, a substance is injected into their body, they lie on a table, and a machine takes images. - A standard computed tomography (CT) scan of the chest, abdomen, and pelvis. - An octreotide scintigraphy Single photon emission computed tomography (SPECT)/CT. - A 68Gallium-DOTATATE positron emission tomography (PET)/CT. The study drug is injected into a vein, usually in the arm. Low-dose X-rays go through the body. For about 40 minutes a large, donut-shaped device takes images of the body. The entire session takes 90 to 120 minutes. - Researchers will compare images from the three scans. - Participants will have 1 follow-up visit each year for 5 years. At this visit, they will have a medical exam, blood taken, and a CT scan.
NCT02078843 ↗ Diagnostic Accuracy of Gallium-68-DOTATATE PET/CT Compared to Indium-111-pentetreotide Scintigraphy (SPECT/CT) for Gastroenteropancreatic Neuroendocrine Tumors Terminated SWAN Isotopen AG, Bern Phase 1/Phase 2 2014-03-01 The investigators hypothesize that the new imaging method Gallium-68-DOTATATE has a higher diagnostic value in the detection of neuroendocrine tumors than the established imaging method Indium-111-Octreoscan. Therefore, the investigators will perform both imaging procedures in patients with suspected or confirmed neuroendocrine tumors. Subsequently, the investigators will compare the diagnostic performance of both methods.
NCT02078843 ↗ Diagnostic Accuracy of Gallium-68-DOTATATE PET/CT Compared to Indium-111-pentetreotide Scintigraphy (SPECT/CT) for Gastroenteropancreatic Neuroendocrine Tumors Terminated University Hospital, Basel, Switzerland Phase 1/Phase 2 2014-03-01 The investigators hypothesize that the new imaging method Gallium-68-DOTATATE has a higher diagnostic value in the detection of neuroendocrine tumors than the established imaging method Indium-111-Octreoscan. Therefore, the investigators will perform both imaging procedures in patients with suspected or confirmed neuroendocrine tumors. Subsequently, the investigators will compare the diagnostic performance of both methods.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for GALLIUM DOTATATE GA-68

Condition Name

Condition Name for GALLIUM DOTATATE GA-68
Intervention Trials
Neuroendocrine Tumors 4
Neuroendocrine Neoplasm 2
Gastroenteropancreatic Neuroendocrine Tumors 2
Hematopoietic and Lymphoid Cell Neoplasm 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for GALLIUM DOTATATE GA-68
Intervention Trials
Neuroendocrine Tumors 11
Carcinoid Tumor 6
Pancreatic Neoplasms 3
Neoplasms 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for GALLIUM DOTATATE GA-68

Trials by Country

Trials by Country for GALLIUM DOTATATE GA-68
Location Trials
United States 21
France 2
China 2
Canada 1
Switzerland 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for GALLIUM DOTATATE GA-68
Location Trials
California 4
Maryland 3
Minnesota 3
Kentucky 2
Alabama 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for GALLIUM DOTATATE GA-68

Clinical Trial Phase

Clinical Trial Phase for GALLIUM DOTATATE GA-68
Clinical Trial Phase Trials
Phase 3 1
Phase 2/Phase 3 1
Phase 2 5
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for GALLIUM DOTATATE GA-68
Clinical Trial Phase Trials
Recruiting 10
Completed 2
Active, not recruiting 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for GALLIUM DOTATATE GA-68

Sponsor Name

Sponsor Name for GALLIUM DOTATATE GA-68
Sponsor Trials
National Cancer Institute (NCI) 7
Jonsson Comprehensive Cancer Center 2
Mayo Clinic 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for GALLIUM DOTATATE GA-68
Sponsor Trials
Other 17
NIH 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.